Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Harvard Business School
Johnson and Johnson
Colorcon

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Patent: 5,801,235

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,801,235
Title: Oligonucleotides with anti-cytomegalovirus activity
Abstract:Disclosed are synthetic oligonucleotides 15 to 50 nucleotides in length which are specifically hybridizable with at least a portion of RNA or DNA derived from the UL36, UL84, UL101x-102, or UL112-113 genes of a cytomegalovirus. Also disclosed are pharmaceutical compositions including an oligonucleotide of the invention and methods of inhibiting cytomegalovirus infection using such oligonucleotides.
Inventor(s): Pari; Gregory S. (North Smithfield, RI)
Assignee: Hybridon, Inc. (Cambridge, MA)
Application Number:08/249,386
Patent Claims:see list of patent claims

Details for Patent 5,801,235

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Hybridon, Inc. (Cambridge, MA) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Hybridon, Inc. (Cambridge, MA) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Hybridon, Inc. (Cambridge, MA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
Mallinckrodt
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.